Format

Send to

Choose Destination
Thorax. 2002 Apr;57(4):343-7.

Randomised trial of intrapleural urokinase in the treatment of childhood empyema.

Author information

1
Department of Paediatrics, John Radcliffe Hospital, Oxford, UK. anne.thomson@orh.nhs.uk

Abstract

BACKGROUND:

The role of intrapleural fibrinolytic agents in the treatment of childhood empyema has not been established. A randomised double blind placebo controlled trial of intrapleural urokinase was performed in children with parapneumonic empyema.

METHODS:

Sixty children (median age 3.3 years) were recruited from 10 centres and randomised to receive either intrapleural urokinase 40 000 units in 40 ml or saline 12 hourly for 3 days. The primary outcome measure was length of hospital stay after entry to the trial.

RESULTS:

Treatment with urokinase resulted in a significantly shorter hospital stay (7.4 v 9.5 days; ratio of geometric means 1.28, CI 1.16 to 1.41 p=0.027). A post hoc analysis showed that the use of small percutaneous drains was also associated with shorter hospital stay. Children treated with a combination of urokinase and a small drain had the shortest stay (6.0 days, CI 4.6 to 7.8).

CONCLUSION:

Intrapleural urokinase is effective in treating empyema in children and significantly shortens hospital stay.

PMID:
11923554
PMCID:
PMC1746300
DOI:
10.1136/thorax.57.4.343
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center